Adaptimmune Annual report pursuant to Section 13 and 15(d)

Contingencies and commitments - Collaborations and License Agreements (Details)

Contingencies and commitments - Collaborations and License Agreements (Details) - USD ($)			1 Months Ended			12 Months Ended
	Jan. 13, 2020	Jun. 16, 2016	Jun. 30, 2019	Feb. 29, 2016	Nov. 30, 2015	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2012	Sep. 26, 2016
Collaboration and License Agreement
Purchasing obligations							$ 5,000,000
ThermoFisher
Collaboration and License Agreement
Supply contract agreement period (in years)		5 years
MD Anderson Strategic Alliance
Collaboration and License Agreement
Upfront license fees									$ 3,412,000
License agreement \| MD Anderson Strategic Alliance
Collaboration and License Agreement
Milestone payments						$ 3,549,000		$ 2,325,000
License agreement \| MD Anderson Strategic Alliance \| Minimum
Collaboration and License Agreement
Potential milestone payments											$ 19,644,000
Astellas Collaboration Agreement \| Maximum
Collaboration and License Agreement
Milestone payments	$ 552,500,000
Astellas Collaboration Agreement \| Universal Cells, Inc.
Collaboration and License Agreement
Potential milestone payments						$ 37,600,000
Upfront license and start-up fees					$ 2,500,000
Milestone payments				$ 3,000,000				$ 200,000	$ 900,000
Astellas Collaboration Agreement \| Life Technologies Corp
Collaboration and License Agreement
Upfront license fees										$ 1,000,000
Minimum annual royalties as a percentage of prior year running royalties (as a percent)						50.00%
Astellas Collaboration Agreement \| Noile Immune Biotech Inc.
Collaboration and License Agreement
Upfront license fees							2,500,000
Astellas Collaboration Agreement \| Noile Immune Biotech Inc. \| Maximum
Collaboration and License Agreement
Potential milestone payments						$ 312,000,000
Astellas Collaboration Agreement \| Alpine Immune Sciences Inc.
Collaboration and License Agreement
Upfront license fees			$ 2,000,000
Astellas Collaboration Agreement \| Alpine Immune Sciences Inc. \| Maximum
Collaboration and License Agreement
Potential milestone payments			$ 288,000,000
Research and development \| Minimum
Collaboration and License Agreement
Purchasing obligations							5,000,000
Research and development \| Astellas Collaboration Agreement \| Alpine Immune Sciences Inc.
Collaboration and License Agreement
Upfront license fees							$ 2,000,000
Development milestone per product developed unilaterally \| Astellas Collaboration Agreement \| Maximum
Collaboration and License Agreement
Potential milestone payments	147,500,000
Sales milestone for products developed unilaterally \| Astellas Collaboration Agreement \| Maximum
Collaboration and License Agreement
Potential milestone payments	$ 110,000,000